Skip to main content
Marinomed Biotech AG logo

Marinomed Biotech AG — Investor Relations & Filings

Ticker · MARI ISIN · ATMARINOMED6 LEI · 529900GN3B1EN80XF405 VI Manufacturing
Open in API
Filings indexed 432 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country AT Austria
Listing VI MARI

About Marinomed Biotech AG

https://www.marinomed.com/en

Marinomed Biotech AG is a biopharmaceutical company that develops medicinal products and medical devices for viral infectious diseases and immunological disorders. The company's innovation is driven by proprietary, patent-protected technology platforms. The Marinosolv platform enhances the solubility and bioavailability of poorly soluble compounds, enabling the development of treatments for immunological conditions such as allergies, asthma, and inflammatory diseases. The virology platform is the basis for therapies targeting viral respiratory infections. Marinomed maintains a development pipeline, has globally marketed therapeutics, and offers its technology through partnerships and services via its Solv4U unit.

Recent filings

Filing Released Lang Actions
Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv Technology in Inhalation Therapy
Regulatory Filings Classification · 50% confidence The document is a corporate press release announcing a strategic partnership and worldwide licensing agreement for Marinomed’s technology platform. It does not contain financial statements, dividends, regulatory filings, or management changes, nor is it an earnings release or an M&A takeover. It is a general corporate announcement of a licensing agreement, which does not neatly fit any specific category and thus falls into the fallback “Regulatory Filings (RNS)” classification.
2026-05-19 English
EQS-AGM: Marinomed Biotech AG: Invitation to the 9th Annual General Meeting on Thursday, June 11, 2026, at 13:00 (Vienna time)
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal convening notice (“Invitation to the 9th Annual General Meeting”), complete with the agenda, proposed resolutions, record date, proxy forms and shareholder rights. It is sent to shareholders prior to the meeting to request votes and provide meeting information. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-13 English
EQS-HV: Marinomed Biotech AG: Einberufung der 9. ordentlichen Hauptversammlung für Donnerstag, den 11. Juni 2026 um 13:00 Uhr (Wiener Zeit)
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a formal convocation (“Einberufung”) of the 9th Annual General Meeting (Hauptversammlung) including the agenda, voting rights instructions, proxy forms and participation details. It is not the AGM’s presentations (no slide deck or Q&A), nor a financial report, but rather materials sent to shareholders to inform them and solicit their votes. Therefore it best fits the Proxy Solicitation & Information Statement category.
2026-05-13 German
Marinomed Biotech AG: Invitation to the 9th Annual General Meeting on Thursday, June 11, 2026, at 13:00 (Vienna time)
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal convocation notice for the 9th Annual General Meeting on June 11, 2026. It includes the full agenda with proposed resolutions, detailed instructions for record dates, proxy appointments, and shareholders’ rights. This falls under materials sent to shareholders to provide information and request votes for an upcoming general meeting, matching the Proxy Solicitation & Information Statement category rather than the AGM presentation itself or the full annual report.
2026-05-13 English
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
Regulatory Filings Classification · 82% confidence The document is a corporate news/press release announcing Marinomed Biotech AG’s commercial progress with Tacrolimus eyedrops for entry into the compounding market. It does not contain any financial statements, earnings highlights, or regulatory filings but is rather a strategic commercial update. It is not an earnings release, management change, capital raise, or other specific category. Therefore, it falls into the general Regulatory Filings (RNS) category as the catch-all for corporate announcements.
2026-05-11 English
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Total Voting Rights Announcement by Marinomed Biotech AG, referencing a change in total voting rights due to a capital increase. It cites Article 135, Section 1 of the BörseG, which governs announcements of voting rights. The content focuses on the updated number of voting rights and share capital, without detailed financial statements or broader report content. The document length is short (1088 characters), and it is an announcement of voting rights rather than a full report or financial disclosure. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.